Celltrion Pharm Inc Asset Resilience Ratio
Celltrion Pharm Inc asset resilience ratio. Celltrion Pharm Inc (068760) has an Asset Resilience Ratio of 12.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 068760 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Celltrion Pharm Inc (2011–2024)
Asset resilience ratio of Celltrion Pharm Inc from 2011 to 2024. This chart shows how Celltrion Pharm Inc's Asset Resilience Ratio has changed over time. See Celltrion Pharm Inc (068760) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Celltrion Pharm Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Celltrion Pharm Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩93.17 Billion | 12.49% |
| Total Liquid Assets | ₩93.17 Billion | 12.49% |
Asset Resilience Insights
- Moderate Liquidity: Celltrion Pharm Inc has 12.49% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Celltrion Pharm Inc Industry Peers by Asset Resilience Ratio
Compare Celltrion Pharm Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.09% |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907 |
Drug Manufacturers - Specialty & Generic | 14.54% |
Celltrion Pharm Inc Asset Resilience Ratio by Year (2011–2024)
Celltrion Pharm Inc asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Celltrion Pharm Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.48% | ₩63.48 Billion ≈ $43.02 Million |
₩669.46 Billion ≈ $453.69 Million |
+4.46pp |
| 2023-12-31 | 5.02% | ₩32.21 Billion ≈ $21.83 Million |
₩641.64 Billion ≈ $434.83 Million |
-2.33pp |
| 2022-12-31 | 7.35% | ₩44.09 Billion ≈ $29.88 Million |
₩599.72 Billion ≈ $406.42 Million |
-6.47pp |
| 2021-12-31 | 13.82% | ₩88.16 Billion ≈ $59.75 Million |
₩637.88 Billion ≈ $432.29 Million |
+8.39pp |
| 2020-12-31 | 5.43% | ₩29.75 Billion ≈ $20.16 Million |
₩548.07 Billion ≈ $371.42 Million |
+2.60pp |
| 2019-12-31 | 2.83% | ₩13.33 Billion ≈ $9.03 Million |
₩470.98 Billion ≈ $319.18 Million |
+0.82pp |
| 2018-12-31 | 2.02% | ₩9.12 Billion ≈ $6.18 Million |
₩452.44 Billion ≈ $306.61 Million |
+0.75pp |
| 2017-12-31 | 1.27% | ₩5.95 Billion ≈ $4.03 Million |
₩470.27 Billion ≈ $318.69 Million |
-0.79pp |
| 2016-12-31 | 2.06% | ₩10.51 Billion ≈ $7.12 Million |
₩510.02 Billion ≈ $345.63 Million |
+1.91pp |
| 2015-12-31 | 0.15% | ₩715.00 Million ≈ $484.55K |
₩466.77 Billion ≈ $316.32 Million |
-0.79pp |
| 2014-12-31 | 0.94% | ₩3.86 Billion ≈ $2.62 Million |
₩411.16 Billion ≈ $278.64 Million |
-0.66pp |
| 2013-12-31 | 1.60% | ₩5.78 Billion ≈ $3.92 Million |
₩361.35 Billion ≈ $244.88 Million |
-2.12pp |
| 2012-12-31 | 3.72% | ₩12.31 Billion ≈ $8.34 Million |
₩331.04 Billion ≈ $224.34 Million |
-2.99pp |
| 2011-12-31 | 6.70% | ₩14.49 Billion ≈ $9.82 Million |
₩216.08 Billion ≈ $146.43 Million |
-- |
About Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more